What High Lp(a) Means Now: Risk Is Real, Treatment Is Murky

For decades, most doctors paid little attention to a blood lipid called lipoprotein(a), or Lp(a). That is changing dramatically. What high Lp(a) means now has become one of the most intriguing and confusing questions in cardiology. Billions of dollars are at stake for drug companies. Millions of patients are wondering what to do if their Lp(a) levels are elevated. We will try to provide some answers in this new article.

The new 2026 American College of Cardiology/American Heart Association guideline recommends that adults have Lp(a) measured at least once during their lifetime. A level of 125 nmol/L or 50 mg/dL or higher is considered a cardiovascular risk-enhancing factor. At 250 nmol/L or 100 mg/dL, estimated cardiovascular risk is roughly doubled.

Have You Been Tested for High Lp(a)?

The cardiology research community has become increasingly interested in blood testing for high Lp(a) levels. That was in anticipation of a brand-new drug that was supposed to lower this risk factor for heart attacks, strokes, calcified aortic valves and premature death.

But then came a bombshell.

An experimental drug called pelacarsen successfully lowered Lp(a) levels in a huge clinical trial called Lp(a)HORIZON. Key players in the world of cardiology were involved in this research. Over 8,000 people with high Lp(a) levels and established heart disease were involved in the trial. You read about this train wreck at this link.

Here is how I described the unexpected result:

Pelacarsen Failure: Heart Drug Lowers Lp(a) but NOT Heart Attacks
Cardiologists are stunned by the Pelacarsen Failure: Lp(a) plunged, but heart attacks, strokes and deaths did NOT. A bombshell disappointment

The bottom line: Pelacarsen failed to reduce the cardiovascular events researchers were trying to prevent. So where does that leave someone who discovers that Lp(a) is sky high?

A reader of our syndicated newspaper column recently confronted precisely that dilemma.

A Heart Attack Nobody Expected

Q. After reading your article on lipoprotein (a), I wanted to share my experience. In February 2024, I thought I had indigestion. When antacids did not relieve the symptoms, I went to the Emergency Room and was diagnosed with a mild heart attack.

My weight is normal; I exercise often and have well-controlled blood pressure and slightly elevated cholesterol levels. My primary care doctor did not have me on statins.

A heart catheterization revealed that I had four major blockages in my coronary arteries and I had a quadruple bypass operation. My doctor said I was the last patient he would have expected to have heart problems. The cardiologist I have seen since my surgery did not test my Lp(a) levels.

After seeing a news segment, I requested testing. My level was 345 nmol/L!

Although there is currently no treatment available, I believe testing is important. Because of the possible hereditary link, I urged my children to be tested. Their levels are very low. Fortunately, my heart is not damaged, but I am aware of potential risks. Keep urging your readers to be tested.

A. We are shocked that your cardiologist did not order a test for Lp(a). The American College of Cardiology recently updated its guidelines and now recommends that everyone be tested for this risk factor at least once. Your level was extremely high and might well explain why you had a heart attack and clogged arteries.

A new clinical trial of the drug pelacarsen to lower Lp(a) yielded disappointing results. It worked to reduce Lp(a) but did not prevent heart attacks and strokes.

There are other ways to manage this risk. You can learn more about aspirin, niacin, PCSK9 inhibitors and diet in our eGuide to Cholesterol Control & Heart Health. This online resource may be found under the Health eGuides tab.

What High Lp(a) Means Now After Pelacarsen

This reader’s story illustrates why cardiologists have become so interested in Lp(a). People can maintain normal weight, exercise regularly, control their blood pressure and avoid smoking and still suffer serious cardiovascular disease. Sometimes an important inherited risk factor has been hiding in plain sight.

Lp(a) is largely determined by your genes. Roughly one person in five has an elevated level. Unlike LDL cholesterol, however, Lp(a) is not part of the routine cholesterol panel. The American Heart Association now tells patients that the only way to know their level is through a separate blood test. It recommends that every adult be tested at least once.

That recommendation did not disappear when pelacarsen stumbled.

“Why Test for Something You Can’t Treat?”

Michael was 82 when he decided to pay for his own Lp(a) test. He wrote:

“What I find interesting is the reluctance by GPs to do lab testing for Lp(a) along with other lipid panels i.e LDL, HDL and Triglycerides. Some healthcare insurance carriers do not cover it.”

His result was in the low 200s, which alarmed him. He subsequently had a coronary artery calcium scan and learned that he had substantial coronary calcification.

Then he asked his primary care physician why no one had tested his Lp(a) before.

According to Michael:

“He basically blew it off…saying there’s nothing you can do about it so why create anxiety over something you have no control.”

Michael did not agree:

“I’d much rather know the risk ratio than to live in ignorance…which allows me to decide who gets to decide…and control my own destiny through behavior modification.”

That disagreement captures a debate that has been going on inside medicine for decades.

If doctors had no drug to lower Lp(a), why measure it?

The new ACC/AHA guideline supplies a very different answer: because Lp(a) helps identify cardiovascular risk even if there is not yet an FDA-approved drug specifically proven to neutralize that risk.

Knowing about very high Lp(a) can influence how aggressively physicians manage LDL cholesterol, blood pressure, smoking, diabetes and other factors that can be altered. It can also alert relatives because high Lp(a) is largely inherited.

Another Reader Couldn’t Get Her Doctor to Order the Test

Diane encountered an even more direct barrier:

“After reading your articles about LP(a) in the newsletters I asked my PCP to run a test for me. She refused, saying something weird like it wasn’t reliable or radical or something like that.”

Diane was reluctant to argue:

“I do not argue with doctors because I don’t want to be cancelled because I have a reputation as a ‘difficult patient.’”

Eventually, Diane discovered that a local research group was offering Lp(a) testing and signed up. Her result was reassuringly low.

She concluded:

“It bothers me that I had to go through such hoops to get such a simple test run.”

That experience seems especially striking today.

The 2026 ACC/AHA dyslipidemia guideline specifically states that Lp(a) should be measured at least once to identify people at increased risk for atherosclerotic cardiovascular disease.

The American Heart Association has even launched an Lp(a) Discovery Project aimed at improving testing and identifying barriers that keep patients from getting tested.

Times have changed.

The Pelacarsen Paradox

But identifying risk and successfully treating that risk are two different things. For years, the reasoning seemed straightforward:

High Lp(a) is associated with heart attacks, strokes, peripheral arterial disease and aortic valve disease.

So:

Lower Lp(a), and cardiovascular events should fall.

Novartis tested that hypothesis in the enormous Phase III Lp(a)HORIZON trial involving more than 8,000 people with established cardiovascular disease and elevated Lp(a).

Pelacarsen did what it was designed to do: It lowered Lp(a).

But on September 4, 2026, Novartis announced that the drug did not meet the trial’s primary endpoint. It did not significantly reduce the combined risk of cardiovascular death, nonfatal heart attack, nonfatal stroke and urgent coronary procedures requiring hospitalization compared with placebo.

That does not prove that Lp(a) is harmless. It does raise a much harder question:

Is lowering Lp(a) enough to lower cardiovascular risk?

We don’t yet know. Other experimental medicines use different mechanisms and can lower Lp(a) dramatically. Their cardiovascular outcome trials have suddenly become even more important. But we will have to wait awhile to learn the results of these clinical trials.

When High Lp(a) Becomes More Than a Laboratory Number

One of our readers, T.S., illustrates why patients are desperate for answers.

He wrote:

“My Lp(a) was 262 nmol/L, and 500 mg BID Niacin brought it down to 192.”

But his medical history is far more compelling than the laboratory numbers.

T.S. suffered a heart attack at age 49. Now 71, he reports severe peripheral arterial disease, 23 related surgeries and two toe amputations.

His LDL cholesterol is now 48 while taking Repatha plus ezetimibe. But after the disappointing pelacarsen results, the question he wants answered is whether very high-risk patients like him responded differently in the trial.

T.S. wondered:

“I really would like to see the sub-results for very high risk patients who were NOT on statins.”

So would we. Most people (and physicians) do not realize that statins can actually raise Lp(a). Dr. Sotirios (Sam) Tsimikas and his colleagues wrote an article published in the European Heart Journal on January 1, 2020. It was titled:

“Statins and increases in Lp(a): an inconvenient truth that needs attention”

Here is what Dr. Tsimikas, et al. stated:

“Regarding the potential clinical relevance of the increases in Lp(a) noted in our study, which ranged by an average of 8–24%, the data from our current study would suggest it is clinically significant. Even though the mean Lp(a) levels in most trials were <30 mg/dL, this is typical of the Lp(a) distribution in populations. The patients where this is clinically relevant, however, are those with elevated Lp(a) >30–50 mg/dL.”

The complete Lp(a)HORIZON results will matter enormously. The topline announcement does not tell us whether patients starting with exceptionally high Lp(a), people with different background treatments or particular subgroups experienced different outcomes.

For people like T.S., this is anything but an academic debate.

What Can People with High Lp(a) Do Now?

There is still no FDA-approved medicine specifically targeting Lp(a) that has been proved in a dedicated cardiovascular outcome trial to prevent heart attacks and strokes. But that does not mean physicians and patients have nothing to discuss.

PCSK9 Inhibitors Lower Lp(a) Too

The injectable PCSK9 inhibitors evolocumab (Repatha) and alirocumab (Praluent) were developed primarily to lower LDL cholesterol. They also lower Lp(a).

A comprehensive meta-analysis of 147 randomized controlled trials involving 145,314 participants found that PCSK9 monoclonal antibodies reduced Lp(a) by an average of about 29 percent.

A separate analysis of 31 randomized trials (Journal of Clinical Lipidology, June, 2026) found an average Lp(a) reduction of about 26 percent with PCSK9-targeting drugs. What the authors did not report was whether such drugs lowered the rate of heart attacks, strokes, or other cardiovascular events because they lowered Lp(a).

One of our readers named Mike could have been a participant in such a study. He reported:

“You did not mention that Repatha can lower Lp(a) 20-30%. In my case it lowered it 25% although it is still too high.”

His experience lines up remarkably well with the research.

There is, however, an important caveat. Repatha and Praluent dramatically lower LDL cholesterol, and both have demonstrated cardiovascular benefits. Scientists cannot yet say how much of that protection is specifically attributable to their modest effect on Lp(a).

After pelacarsen, that distinction matters more than ever.

What About Niacin?

Long before statins dominated cholesterol treatment, doctors prescribed niacin, also known as nicotinic acid or vitamin B3. Niacin really does lower Lp(a). The large meta-analysis published in the journal Atherosclerosis mentioned above found that niacin lowered Lp(a) by an average of approximately 37 percent compared with placebo.

Research reference: PubMed: Niacin and other lipid-lowering therapies on Lp(a)

T.S.’s numbers went from 262 to 192 nmol/L while he was taking niacin, although an individual experience cannot establish that niacin alone was responsible.

Another reader, Marjorie, reported that her Lp(a) declined from 289 to 145 nmol/L while working with a functional medicine physician. She was using niacin along with red yeast rice and several other products.

That is intriguing, but because she was taking multiple treatments simultaneously, it is impossible to determine which intervention caused the change. There is also a bigger problem.

Modern cardiovascular trials of niacin have not demonstrated the cardiovascular benefits researchers once expected when it was added to statin treatment. And high-dose niacin is not an innocuous nutritional supplement. It can cause severe flushing and itching and can affect liver function, blood sugar and uric acid.

Anyone considering pharmacological doses of niacin should do so under medical supervision.

Could Aspirin Help Some People with High Lp(a)?

This possibility is especially intriguing. That’s because Dr. Sotirios “Sam” Tsimikas, one of the world’s foremost Lp(a) researchers and a previous guest on The People’s Pharmacy, was a coauthor of an analysis of the randomized ASPREE trial.

Researchers studied 12,815 genotyped participants age 70 or older who had been randomly assigned to take 100 mg of aspirin daily or placebo. Among people carrying a particular Lp(a)-associated genetic variant, aspirin reduced major cardiovascular events by 11.4 events per 1,000 person-years. Among people in the highest category of an Lp(a) genetic risk score, the reduction was 3.3 events per 1,000 person-years.

The authors offered this conclusion:

“In this analysis of the ASPREE trial, we found evidence suggesting that older individuals with genotypes associated with elevated Lp(a) levels may benefit from low-dose aspirin for the primary prevention of CVD [cardiovascular disease] events.

“Our results provide new evidence to support the potential use of aspirin to target individuals with elevated Lp(a) for the primary prevention of CVD events.

“…given the lack of any currently approved therapies for targeting elevated Lp(a), our findings may have widespread clinical implications, adding evidence to the rationale that aspirin may be a viable option for reducing Lp(a)-mediated CVD risk. The role of aspirin in primary prevention of CVD remains widely debated. Identification of population subgroups who may benefit from aspirin (in which the net benefit-harm balance shifts favorably) may enable a more guided and precise use of aspirin in primary prevention.”

That study examined genetic markers associated with high Lp(a) rather than simply giving aspirin to everyone whose laboratory Lp(a) was elevated. A subsequent observational study involving people with directly measured Lp(a) provides another intriguing clue.

In the Multi-Ethnic Study of Atherosclerosis (MESA), aspirin use among people with Lp(a) above 50 mg/dL was associated with a significantly lower rate of coronary events. The investigators emphasized, however, that this was an observational analysis and requires confirmation in a randomized trial.

One little observation about aspirin and aortic heart valve disease. Dr. Tsimikas and his colleagues published an observational study in the European Heart Journal, Sept. 8, 2026. This involved 6,598 participants. Remember, people with high Lp(a) levels have a substantially greater likelihood of developing calcified aortic heart valves. This is clearly not a good thing!

Roughly one-fourth of people between 65 and 74 have signs of aortic valve sclerosis. When people reach their mid-80s that number climbs to almost 50%. When heart valves become seriously calcified, they increase the risk for heart attacks and other cardiovascular complications. By the way, statins do not protect against this problem.

The authors of the most recent aspirin study concluded:

“In this exploratory observational analysis, among individuals with elevated Lp(a), those who reported regular aspirin had a ≥60% lower long-term risk of incident AVC [aortic valve calcium] and severe AS. [aortic stenosis].”

A Word of Caution About Aspirin:

No one should start taking daily aspirin solely because an Lp(a) test comes back high without discussing the potential benefits and risks with a physician. Aspirin can cause bleeding and may interact with a number of other medications.

Can Diet Affect Lp(a)?

Patients have traditionally been told that because Lp(a) is primarily controlled by genes, diet and exercise won’t make much difference. Genes certainly dominate. But the old idea that “diet makes no difference” may be too absolute.

A randomized controlled feeding study assigned 164 people who had lost weight to low-, moderate- or high-carbohydrate diets.

Lp(a) fell by 14.7 percent on the low-carbohydrate diet, compared with a 2.1 percent decline on the moderate-carbohydrate diet and essentially no change on the high-carbohydrate diet.

The authors reported that they found reduced carbohydrate intake had a variety of benefits, including for insulin resistance.

“In addition, we found a potentially novel dietary effect on Lp(a), a major independent and causal risk factor for atherosclerosis. A recent review of trials ranging from 3 to 8 wk reported that “diet modestly affects Lp(a) and often in the opposing direction to LDL-C,” consistent with findings from the Delta Study in 1998.”

That does not prove that lowering Lp(a) with a low-carbohydrate diet prevents heart attacks. The investigators themselves called for trials measuring actual cardiovascular outcomes.

After the pelacarsen disappointment, that distinction has become impossible to ignore.

What High Lp(a) Means Now: Know the Risk, Not Just the Number

We think there is a lesson in the stories our readers have shared.

• The reader who introduced this article had a heart attack and four severely clogged coronary arteries despite normal weight, regular exercise and well-controlled blood pressure.
• T.S. suffered a heart attack at 49 and has experienced devastating peripheral arterial disease.
• Michael wanted his Lp(a) measured but encountered the attitude that knowing about an untreatable risk factor would merely create anxiety.
• Diane’s doctor actually declined to order the test, forcing her to find another way to obtain it.

Those last two experiences are especially noteworthy today.

The 2026 ACC/AHA guideline now says:

Measure Lp(a) at least once.

Finding a high value does not mean catastrophe is inevitable. Nor does finding a drug or diet that lowers Lp(a) prove that heart attacks will be prevented. The pelacarsen trial has made that lesson painfully clear.

But knowing that someone carries substantial inherited cardiovascular risk can influence how physicians and patients approach the risk factors they can modify. It can also alert siblings and children who might otherwise never know that elevated Lp(a) runs in their family.

For the moment, perhaps the most useful first step is remarkably simple:

Know your number!

Have you ever asked to have your Lp(a) measured? Did your physician order the test willingly, or did you encounter resistance? If your Lp(a) was high, what did your doctor recommend? And have you suffered cardiovascular problems despite normal cholesterol, healthy eating and regular exercise? Maybe some of the strategies we have mentioned above may be helpful, with medical supervision.

Final Words:

Please share your story in the comment section below. Your experience may help other readers ask questions they never realized they needed to ask.

You can learn more about Lp(a), LDL cholesterol, aspirin, niacin, PCSK9 inhibitors and nondrug approaches in our eGuide to Cholesterol Control & Heart Health under the Health eGuides tab. If you think there is useful information in this article, please share it with friends and family.